Drug Could Reduce Solid Tumor Growth
For people with advanced, metastasized solid tumors, a clinical trial available through OHC (Oncology Hematology Care) is evaluating a drug that could reduce tumor cell growth.
Sitravatinib (MGCD516) is being tested in clinical trials to determine whether or not it is effective in reducing tumor cell growth as well as how the body processes and metabolizes the drug, dosage and concentration, and overall safety.
Right now the excitement, and rightly so, in terms of cancer treatment is immunotherapy – where we re-train the body’s own immune system to attack and kill cancer cells. Although there has been promising results with blood cancers, we still have a long way to go to determine its effectiveness in treating solid tumors. For this reason, we continue to test drugs like sitravatinib to give patients with advanced, solid tumors a chance at remission with quality of life.
The study is for cancer patients with genetic mutations involving sitravatinib targets. As of December 2016, a total of six patients with non-small cell lung cancer (NSCLC) with RET fusion mutations* had been enrolled, four of whom were evaluable, and tumor reduction was observed in all four of these patients. The longest duration on study is more than 46 weeks and the patient remains on study.
It’s still early in the trial phase but so far, the results are promising.
For more information about this and other clinical trials at OHC, call 1-888-649-4800 or visit www.ohcare.com/patient-resources/clinical-trials/available-trials/.
OHC has been fighting cancer on the front lines for more than three decades. We are the region’s leading experts in the treatment of nearly every form of adult cancer and complex blood disorder. OHC offers the latest medical, gynecologic and radiation therapy, and is always seeking better treatment options through participation in clinical trials. OHC is certified by the American Society for Clinical Oncology in the Quality Oncology Practice Initiative Certification Program, is the only accredited Oncology Medical Home in Cincinnati and is one of only 196 cancer practices nationally to be accepted into the Medicare Oncology Initiative. At its heart, our approach to cancer care is simple – to surround you with everything you need so you can focus on what matters most: beating cancer.
* About 1 in 75 NSCLCs have a change in the RET gene that alters the RET protein. The most common change is a gene fusion. RET fusions are more common in adenocarcinomas, a type of NSCLC.